Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...

In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...

Nov 5 (Reuters) - Novavax (NVAX.O), opens new tab said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency (UKHSA) related to its COVID-19 ...

Shares in Novavax fell by as much as one-fifth Wednesday morning after the company disclosed the Food and Drug Administration halted clinical testing of its combination vaccine for COVID-19 and ...

Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put two of the biopharma's programs on hold in response to a case of nerve disease from a former ...

Novavax ( (NVAX)) has issued an announcement. Novavax, Inc. and the UK Health Security Agency have reached a settlement to terminate their SARS-COV-2 Vaccine Supply Agreement, resolving disputes ...

Graeme Sloan / Bloomberg via Getty Images The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its standalone flu shot because of safety concerns.

Oct 16 (Reuters) - The U.S. Food and Drug Administration has put on hold a trial of Novavax's (NVAX.O), opens new tab COVID-influenza and its standalone flu vaccines after a participant who took ...

Shares of Novavax (NASDAQ:NVAX) fell roughly 30% Wednesday morning after the U.S. FDA put a clinical hold on the new drug application of its COVID-19 and influenza combination vaccine and ...

FDA places a clinical hold on Novavax's COVID-19-influenza vaccine trials due to a serious adverse event in a Phase 2 participant. Novavax's COVID-19 IND and European approval for its updated ...